A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak płuca drobnokomórkowy w zaawansowanym stadium, który wymaga pierwszego leczenia.
- •Dobry ogólny stan zdrowia (zdolność do wykonywania codziennych czynności).
- •Widoczne zmiany chorobowe na badaniach obrazowych.
- •Podejrzenie przerzutów do mózgu wymaga wykonania badania mózgu przed rozpoczęciem badania.
✗ Disqualifies
- •Wcześniejsze leczenie raka płuca drobnokomórkowego w stadium ograniczonym.
- •Aktywne, objawowe przerzuty do mózgu.
- •Przebyte choroby płuc wymagające leczenia sterydami lub widoczne zmiany chorobowe na badaniu obrazowym płuc.
- •Inne poważne choroby, które mogłyby wpłynąć na udział w badaniu lub znacząco skrócić oczekiwaną długość życia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (57)
Yale University School of Medicine /ID# 278181
New Haven, United States
Ocala Oncology Center /ID# 278269
Ocala, United States
Moffitt Cancer Center /ID# 277573
Tampa, United States
Fort Wayne Medical Oncology And Hematology /ID# 277336
Fort Wayne, United States
Baptist Health Lexington /ID# 277729
Lexington, United States
Dana-Farber Cancer Institute /ID# 277732
Boston, United States
Missouri Cancer Associates /ID# 278299
Columbia, United States
University Hospitals Cleveland Medical Center /ID# 277556
Cleveland, United States
The University of Texas MD Anderson Cancer Center /ID# 277929
Houston, United States
Virginia Cancer Specialists - Fairfax /ID# 278298
Fairfax, United States
Grand Hopital de Charleroi - Les Viviers /ID# 276897
Charleroi, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 276783
Liège, Belgium
Jessa Ziekenhuis - Campus Virga Jesse /ID# 276781
Hasselt, Belgium
AZ Maria Middelares /ID# 277027
Ghent, Belgium
Cancer Hospital - Chinese Academy of Medical Sciences /ID# 277167
Beijing, China
The First affiliated hospital of Nanchang University - Nanchang /ID# 277247
Nanchang, China
Shanghai East Hospital /ID# 277111
Shanghai, China
Shanghai Pulmonary Hospital /ID# 276960
Shanghai, China
Lungenfachklinik Immenhausen /ID# 278005
Immenhausen, Germany
Universitaetsklinikum Giessen und Marburg GmbH /ID# 277466
Marburg, Germany
Evangelische Lungenklinik Berlin /ID# 277094
Berlin, Germany
Meir Medical Center /ID# 277292
Kefar Sava, Israel
Assuta Ashdod Medical Center /ID# 276661
Ashdod, Israel
The Chaim Sheba Medical Center /ID# 276660
Ramat Gan, Israel
Rambam Health Care Campus- Haifa /ID# 276663
Haifa, Israel
Hadassah Medical Center-Hebrew University /ID# 276662
Jerusalem, Israel
National Cancer Center Hospital East /ID# 277239
Kashiwa-shi, Japan
Shizuoka Cancer Center /ID# 277243
Sunto-gun, Japan
Tokyo Metropolitan Komagome Hospital /ID# 277335
Bunkyo Ku, Japan
National Cancer Center Hospital /ID# 277237
Chuo-Ku, Japan
Wakayama Medical University Hospital /ID# 277260
Wakayama, Japan
Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeyla /ID# 276907
Poznan, Poland
Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 276910
Lublin, Poland
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 277112
Warsaw, Poland
University Clinical Center Serbia /ID# 277007
Belgrade, Serbia
Clinical Hospital Center - Bežanijska Kosa /ID# 277013
Belgrade, Serbia
University Clinical Center Nis /ID# 277180
Niš, Serbia
Institute For Pulmonary Diseases Of Vojvodina /ID# 277003
Kamenitz, Serbia
University Clinical Center Kragujevac /ID# 277179
Kragujevac, Serbia
National Cancer Center /ID# 277434
Goyang-si, South Korea
Chungbuk National University Hospital /ID# 277429
Cheongju-si, South Korea
Seoul National University Hospital /ID# 277271
Seoul, South Korea
Yonsei University Health System Severance Hospital /ID# 277597
Seoul, South Korea
Asan Medical Center /ID# 277603
Seoul, South Korea
Samsung Medical Center /ID# 277615
Seoul, South Korea
Complejo Hospitalario Universitario A Coruña /ID# 276922
A Coruña, Spain
Hospital Regional Universitario de Malaga /ID# 276927
Málaga, Spain
Hospital Clinic de Barcelona /ID# 276878
Barcelona, Spain
Hospital Universitario 12 de Octubre /ID# 277251
Madrid, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277267
Kaohsiung City, Taiwan
Kaohsiung Chang Gung Memorial Hospital /ID# 277725
Kaohsiung City, Taiwan
Chung Shan Medical University Hospital /ID# 277660
Taichung, Taiwan
Taipei Veterans General Hospital /ID# 277263
Taipei, Taiwan
Linkou Chang Gung Memorial Hospital /ID# 277264
Taoyuan City, Taiwan
Gazi University Medical Faculty /ID# 276843
Ankara, Turkey (Türkiye)
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 277076
Ankara, Turkey (Türkiye)
Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 276839
Istanbul, Turkey (Türkiye)
Trial contact
ABBVIE CALL CENTER
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.